+86 16650237703
Author:Kangdi 15-09-2026
Pain Patch in Pharmacy Chains EU 2026: Boots, dm, Müller Distribution Guide for OEM Brands
Walking into a Boots in London, a dm drogerie in Berlin, or a Müller in Vienna, you will find pain patches on the health shelf — 12 to 30 SKUs per store, arranged by category (heat, cooling, herbal, lidocaine) and price tier (€2.99 economy to €9.99 premium). These three chains represent 18,000+ stores across the UK, Germany, Austria, Switzerland, Hungary, Croatia, and Spain. Getting a pain patch SKU listed in any of them is a B2B milestone — but the path is paved with regulatory, retailer-specific, and operational requirements most OEM brands underestimate.
Kangdi Medical has supplied private-label pain patches to 14 European pharmacy chains since 2015, including Boots UK, dm drogerie-markt, Müller, Rossmann, Superdrug, and Manor. This guide shares the realistic pathway, timelines, and unit economics for OEM brands targeting the European pharmacy channel in 2026.
1. The European Pharmacy Channel by Numbers
| Chain | Countries | Stores | Pain Patch Shelf Facings (typical) | Avg. Retail Price |
|---|---|---|---|---|
| Boots (Walgreens Boots Alliance) | UK, Ireland, Netherlands, Norway | ~2,200 | 18–25 | £3.50 – £9.99 |
| dm drogerie-markt | Germany, Austria, Czechia, Slovakia, Hungary, Croatia, Slovenia, Romania, Bulgaria | ~4,000 | 15–30 | €2.99 – €8.99 |
| Müller (Müller Handels GmbH) | Germany, Austria, Switzerland, Hungary, Spain, Croatia | ~900 | 12–20 | €3.49 – €9.99 |
| Rossmann | Germany, Poland, Czechia, Hungary, Turkey | ~4,400 | 15–25 | €2.79 – €7.99 |
| Superdrug | UK, Ireland | ~800 | 10–18 | £2.99 – £7.99 |
| Manor | Switzerland | ~50 department stores | 8–15 | CHF 4.90 – CHF 12.90 |
| Holland & Barrett | UK, Ireland, Spain, Netherlands, UAE, India | ~1,000 | 10–20 | £3.49 – £11.99 |
The combined annual pain patch volume across these seven chains exceeds 120 million units. Private-label (own-brand) accounts for 35–55% of category sales; the rest is split between leading brands (Hansaplast, Voltaren, Icy Hot, Tiger Balm, Kinesio) and emerging challengers.
2. Boots UK: Category Buyer Requirements
Walgreens Boots Alliance (WBA) operates the Boots UK category through a centralised buying office in Nottingham. Pain patches sit under the category manager for "Health & Wellness Pain Relief".
Listing requirements
- MHRA registration — product must hold a valid UKCA mark for medical devices (post-Brexit) or be accepted under the CE mark transition rules until 30 June 2030.
- Product Liability Insurance — minimum £2 million per claim, WBA as additional insured.
- Artwork proof — Boots brand book compliance, 100% recyclable packaging by 2027 (claim must be substantiated).
- Labelling — UK English, includes British Sign Language video link (voluntary but rewarded), barcode EAN-13, batch code visible on outer.
- Own-brand option — Boots sells "Boots Pharmaceuticals" private label; supplier typically provides exclusive formulas with 12-month NPD exclusivity.
- Sustainable sourcing — palm oil RSPO certified, cotton Better Cotton, recycled content audit.
Timeline and cost
| Step | Duration | Owner |
|---|---|---|
| Initial buyer presentation + sample submission | 2–4 weeks | Supplier |
| Category review (quarterly buyer cycle) | 12–20 weeks | Boots |
| Lab testing + stability + claim substantiation | 8–12 weeks | Supplier |
| Range plan approval + PO | 4–6 weeks | Boots |
| First delivery to RDC (Wakefield, UK) | 8–10 weeks | Supplier |
| In-store launch | 2–4 weeks | Boots |
| Total end-to-end | 9–15 months | — |
Boots typically targets a retail margin of 38–45% on health items and expects trade marketing contributions (3–5% of net sales) for new listings and seasonal campaigns.
3. dm drogerie-markt Germany: Category Buyer Requirements
dm drogerie-markt is Germany's second-largest drugstore chain (after Rossmann), with ~4,000 stores. Pain patches are listed under the category "Schmerzmittel" (pain remedies) alongside topical creams and TENS devices.
Listing requirements
- CE mark under MDR 2017/745 — strictly enforced; dm verifies EUDAMED registration as part of onboarding.
- PZN (Pharmazentralnummer) — German pharmacy central number; mandatory for all OTC products, assigned by IFA GmbH (€90 fee).
- German labelling — IFU in German, including § 4 of German Medical Devices Implementation Act (MPDG).
- Recyclable packaging — dm "Mission 2030" requires mono-material or easily separable components.
- Microplastic-free claim — increasingly required; dm audits for microplastics in the patch matrix.
- Private label option — dm sells "dm" own-brand; supplier provides exclusive formulas under 18-month exclusivity.
Timeline and cost
dm runs two buyer cycles per year (spring/autumn), with decisions made 8–12 months before launch. First contact via the dm category buyer for "Wohlbefinden & Gesundheit" (Wellbeing & Health).
| Step | Duration | Owner |
|---|---|---|
| Supplier pitch + first sample kit | 3–4 weeks | Supplier |
| Buyer review (spring or autumn cycle) | 12–16 weeks | dm |
| Lab + stability + claim verification | 8–12 weeks | Supplier |
| Range plan approval | 4–8 weeks | dm |
| First delivery to dm RDC (Karlsruhe) | 10–12 weeks | Supplier |
| In-store launch | 2 weeks | dm |
| Total end-to-end | 10–14 months | — |
dm operates a tiered margin structure: 38–42% on private label, 30–36% on branded SKUs. Slotting fees are uncommon, but dm demands trade marketing contributions of 4–7% of net sales for category leadership.
4. Müller (DACH + expansion): Category Buyer Requirements
Müller Handels GmbH & Co. KG runs ~900 stores in Germany, Austria, Switzerland, Hungary, Croatia, and Spain. Pain patches sit under "Gesundheit & Wellness" with dedicated buyer teams in each country.
Listing requirements
- CE MDR + country-specific compliance — Austria, Switzerland, Hungary all recognise CE marks; Spain requires Spanish labelling per AEMPS guidance.
- PZN (Germany) + AT code (Austria) + Swissmedic reference — multi-country listing is required for cross-DACH distribution.
- POS artwork — Müller brand book compliance, "Müller Premium" tier requires matte-finish packaging and gold-foil accents.
- Sustainability claims — Müller "Green Müller" program requires FSC cartons, soy ink, and CO₂-neutral shipping.
- Spanish market — Müller Spain requires AEMPS-registered manufacturer + Spanish labelling for any medical device claim.
Timeline and cost
Müller uses quarterly buyer cycles. First contact via the country-specific category buyer (Germany = Ulm HQ; Austria = Vöcklabruck; Switzerland = Lucerne; Spain = Madrid).
| Step | Duration | Owner |
|---|---|---|
| Country-specific buyer presentation | 3–6 weeks | Supplier |
| Buyer review (quarterly) | 8–12 weeks | Müller |
| Lab testing (multiple countries) | 10–14 weeks | Supplier |
| Range plan + trade agreement | 4–8 weeks | Müller |
| Multi-country delivery to RDCs | 10–14 weeks | Supplier |
| In-store launch (staggered) | 4–8 weeks | Müller |
| Total end-to-end | 10–16 months | — |
Müller demands retail margins of 36–42% and reserves right to delist any SKU underperforming 40% sell-through in 8 weeks. KPIs are aggressive — Müller expects 70%+ sell-through on promotional SKUs.
5. Unit Economics: FOB vs Landed vs Retail
Pain patch unit economics vary dramatically by channel. The same Kangdi private-label patch (10x13cm capsicum plaster, 12-pack) sold through different retailers shows the following waterfall:
| Stage | Cost Component | Boots UK | dm Germany | Müller DACH |
|---|---|---|---|---|
| FOB China (12-pack) | Manufacturing | $1.20 | $1.20 | $1.20 |
| Sea freight + insurance | Logistics | $0.30 | $0.30 | $0.30 |
| Duty (HS 3004.90, ~0–6.5% EU) | Import | £0.04 | €0.05 | €0.05 |
| EU Importer fees | Compliance | £0.10 | €0.08 | €0.10 |
| Importer markup (15–25%) | Distribution | £0.30 | €0.25 | €0.28 |
| Landed at retailer RDC | — | £1.94 | €1.88 | €1.93 |
| Retailer margin (38–45%) | Retailer | £1.50 | €1.30 | €1.30 |
| Trade marketing contribution | Marketing | £0.10 | €0.10 | €0.12 |
| Retail VAT (UK 20% / DE 19% / AT 20%) | Tax | £0.79 | €0.65 | €0.68 |
| Shelf price (12-pack) | — | £4.33 | €3.93 | €4.03 |
Note: Private-label listings typically have higher retailer margins (40–48%) but lower absolute retail prices. Branded listings command higher retail prices but face stricter listing criteria.
6. Private Label vs Branded Strategy
| Dimension | Private Label (Retailer Brand) | Branded (Your Brand) |
|---|---|---|
| Margin to supplier (FOB) | Low (5–12% gross) | Higher (25–40% gross) |
| Volume per listing | High (200k–1M units/year) | Moderate (50k–300k units/year) |
| Marketing responsibility | Retailer-funded | Supplier-funded (3–7% net sales) |
| Time to first PO | 9–14 months | 12–18 months |
| Formulation control | Shared with retailer | Full ownership |
| Pricing control | None | Suggested retail price |
| Cross-retailer risk | Exclusive territory restrictions | None — multi-list |
| Brand equity built | Retailer-owned | Supplier-owned |
Kangdi's recommendation for first-time European market entry: launch with private label in 1–2 chains for 12–18 months to validate the supply chain and shelf performance, then add branded SKUs in years 2–3.
7. Compliance Documents Retailers Demand
European pharmacy chains audit suppliers at onboarding and at 12–24 month intervals. The standard documentation package:
- ISO 13485:2016 certificate (current, audited within last 12 months)
- CE certificate (MDR 2017/745) with Notified Body number
- Declaration of Conformity per product SKU
- EUDAMED registration confirmation with UDI-DI and SRN
- EU Authorised Representative contract + AR details
- Lab test reports: biocompatibility (ISO 10993-1), stability (ICH Q1A), microbiological (ISO 11737)
- Clinical Evaluation Report (CER) per MDCG 2020-13
- Post-Market Surveillance Plan
- Product Liability Insurance certificate (€2–10M)
- Recall procedure with mock-recall evidence
- Modern Slavery Statement (UK retailers)
- Sustainability report + CO₂ footprint per SKU
- Conflict mineral declaration (REACH compliance)
- MSDS (Material Safety Data Sheet) for patch components
- Code of Conduct signed by supplier leadership
Kangdi provides all 15 documents in a compliance dossier PDF ready for retailer submission, typically within 3 business days of request.
8. Common Mistakes OEM Brands Make in EU Pharmacy Listing
- Underestimating timeline. Most first-time suppliers expect 6–9 months; realistic is 10–16 months.
- Treating Boots, dm, and Müller as one market. They have different buyers, POs, payment terms, and quality standards.
- Submitting the same SKU to all three chains simultaneously. Each chain expects exclusive formulations in 60–70% of private-label cases. Single-SKU strategy fails.
- Ignoring local labelling rules. German IFU ≠ UK IFU ≠ Spanish IFU. Multilingual labelling is mandatory and adds 6–10 weeks to artwork proof cycle.
- Skipping the in-store visit. Buyers expect suppliers to know the shelf — visit 5 stores per chain pre-pitch, document competitor SKUs and pricing.
- Under-pricing on first PO. Buyers anchor on first price; recovery on subsequent POs is rare. Price in the long-term cost base, not the entry price.
- Missing category buyer windows. dm spring buyer window closes in early February for autumn launch. Missing the cycle costs 6 months.
- No dedicated European sales lead. Buyers ignore suppliers who only respond from China HQ. A Munich / London / Düsseldorf-based rep makes 3× the difference.
- Ignoring private label restrictions. Some chains require exclusive territory; verify before signing exclusive agreements with multiple retailers.
- Neglecting KPI reporting. Chains want weekly sell-through data, monthly inventory, quarterly business reviews. No data = delist within 6 months.
9. What Kangdi Provides for European Pharmacy Listings
- Multi-formulation private label — capsicum, menthol, eucalyptus, lidocaine, herbal blends, each with exclusive territory clauses.
- Full EU compliance dossier — ISO 13485, CE MDR, EUDAMED, EU AR contract, 15-document package ready for retailer submission.
- Multilingual artwork — 24 EU languages covered, including UK English, German, Austrian German, Swiss German, French, Italian, Spanish, Hungarian, Croatian.
- EU Importer / AR partnerships — pre-vetted partners in DE, AT, CH, UK, ES.
- Buyer meeting support — Kangdi team joins first buyer presentation (in-person or video) with category buyer pitch deck.
- Trade marketing creative — shelf wobblers, end-cap displays, seasonal POS materials for Boots, dm, Müller, Rossmann, Superdrug, Manor.
- KPI dashboard — weekly sell-through reporting via retailer portal integration.
- Volume flexibility — 100-piece MOQ for trial orders, scale to 4M pieces/day for full private-label rollout.
10. Frequently Asked Questions (FAQ)
Q1. Can I start with one chain and expand later?
Yes. Most successful EU pharmacy brands launch in one chain, learn the supply chain, then expand in year 2 or 3. Boots-only or dm-only launches are common entry strategies.
Q2. Do pharmacy chains accept private label from Chinese OEM factories?
Yes, but only with full CE MDR compliance, EUDAMED registration, ISO 13485 certification, and an EU Authorised Representative. Kangdi's existing relationships with 14 chains demonstrate this path is well-trodden.
Q3. What's the typical first PO size?
Boots: 100k–300k units per SKU. dm: 200k–500k units. Müller: 80k–250k units. Most chains do trial POs first (30k–50k units) to validate shelf performance.
Q4. How long is the listing cycle from first contact to shelf?
9–16 months end-to-end depending on chain and product complexity. Kangdi's record is 8 months (urgent Boots UK private-label launch for flu season).
Q5. What is the PZN and how do I get one?
PZN (Pharmazentralnummer) is the German pharmacy central number required for all OTC products. Issued by IFA GmbH (Informationsstelle für Arzneimittel) for ~€90 per SKU. Apply via ifaffm.de.
Q6. Do I need separate listings for Austria, Switzerland, Spain?
Yes, if you want full multi-country distribution. Müller requires country-specific listings in each market it operates. Country-specific labelling and buyer relationships are essential.
Q7. What happens if my SKU underperforms?
Most chains delist after 8–12 weeks of sell-through below 40% of plan. Kangdi's KPI dashboard catches underperformance early and supports promotional interventions.
Q8. Can Kangdi help with category buyer introductions?
Yes. Kangdi has direct category buyer contacts at Boots UK, dm Germany, Müller DACH, Rossmann, Superdrug, Holland & Barrett, and Manor. We join first buyer meetings and support ongoing commercial relationship management.
Q9. What payment terms do European chains use?
Standard terms: 30–60 days net from invoice (Boots), 45 days net (dm), 30–60 days net (Müller). New suppliers typically receive 60–90 days for the first 6 months until trust is established.
Q10. Can I list the same product in dm Germany and dm Austria?
Yes, but dm treats these as separate buyers with separate listings, POs, and PZN (Germany only). Austrian dm uses the AT code system managed by the Austrian pharmacy chamber.
11. Decision Matrix: Which Chain to Target First?
| Criteria | Boots UK | dm Germany | Müller DACH | Rossmann DE | Superdrug UK |
|---|---|---|---|---|---|
| Entry barrier | High | Medium-High | Medium | Medium | Medium-Low |
| Time to first PO | 9–15 months | 10–14 months | 10–16 months | 10–14 months | 6–10 months |
| Volume potential | High (UK) | High (DE+) | Medium (DACH) | High (DE+PL) | Medium (UK) |
| Retail margin | 38–45% | 30–42% | 36–42% | 32–40% | 35–42% |
| Private label opportunity | Strong (Boots Pharmaceuticals) | Strong (dm own-brand) | Moderate (Müller Premium) | Strong (Rossmann) | Moderate |
| Sustainability bar | Very high | Very high | High | High | Medium |
| Best for brand category | Premium UK positioning | Mass-market DE | DACH premium/mid-tier | Mass-market DE+PL | Mid-market UK |
12. Next Steps for OEM Brands Targeting EU Pharmacies
- Define target chain + market. Start with one chain — Boots UK or dm Germany are the most common entry points.
- Confirm formulation + packaging brief. Kangdi's NPD team develops chain-specific formulas with 12-month exclusivity.
- Initiate buyer contact. Kangdi joins first buyer meeting with pitch deck + sample kit.
- Submit compliance dossier. 15-document package delivered within 3 business days.
- Lab test cycle. 8–12 weeks of biocompatibility, stability, microbiological testing.
- Range plan + first PO. Buyer approval → PO → production → first delivery.
- In-store launch + KPI reporting. Weekly sell-through reporting from week 1.
Contact Kangdi Medical for a buyer introduction in your target chain. We support the entire pathway — NPD, compliance, artwork, logistics, and post-launch KPI tracking.
Get in touch: Request a buyer introduction · sales@kangdimedical.com · WhatsApp +86-371-XXXX-XXXX
About Kangdi Medical: With 37 years of transdermal patch manufacturing, ISO 13485 certification, and active CE MDR certificates, Kangdi supplies private-label pain patches to 14 European pharmacy chains including Boots UK, dm drogerie-markt, Müller, and Rossmann. Daily capacity 4,000,000 pieces. MOQ 100 pieces for trial orders.